Nkarta develops cell therapies using natural killer cells from healthy donors and relies on global suppliers for essential materials. A key vendor in Germany provides unique instruments and chemicals necessary for manufacturing, which can have a limited shelf life, complicating inventory management. Upcoming pharmaceutical tariffs could raise costs for Nkarta, challenging their clinical development. The broader pharmaceutical supply chain, built over decades, is complex and interconnected, making it difficult for companies to shift manufacturing back to the U.S.
Nkarta isolates immune cells called natural killer cells from healthy donors and engineers them for therapeutic purposes, but relies on global suppliers for key materials.
Pharmaceutical tariffs set to begin at the end of the month could increase manufacturing costs for clinical-stage companies like Nkarta which depend on imported supplies.
Collection
[
|
...
]